drugset / Trial / NCT01068145

Two-Part Study to Evaluate the Dose Response of SCH 527123 on Sputum Neutrophilia Following Ozone Challenge in Healthy Subjects and Chronic Obstructive Pulmonary Disease (COPD) Patients (P05567 AM7)

NCT01068145

Phase 1 Terminated 18 enrolled Merck Sharp & Dohme LLC
RandomizedCrossoverDouble-blind

Summary

Trial to evaluate the dose response of SCH 527123 in reducing inflammation from an ozone-induced sputum neutrophilia in both healthy subjects and subjects with COPD.

Timeline

Start
2010-02
Primary completion
2011-03
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject NAVARIXIN ANHYDROUS Small molecule Oral